Bharat Biotech Vaccine
Fair Pharma Scorecard
Applying human rights to pharma
Menu
Click on ‘Explanation about the score’ sign next to each entry to expand and learn more.
The company should publicly commit to human rights in relation to product development and marketing, by adopting an official human rights policy statement recognising the right to the highest attainable standard of health. The company should endeavour to integrate human rights into its strategies, policies, programmes, projects, and activities.
The company should also have a publicly available global access plan for their Covid-19 product, based on human rights standards, with measurable targets and lines of accountability.
Vaxine has not published a global access plan for its vaccine.
Vaxine has not made any commitment to comply with human rights.
The company should constructively engage with international initiatives for the equitable distribution of vaccines and therapeutics, such as the Covid-19 Technology Access Pool (C-TAP) or the Medicines Patent Pool (MPP), and the ACT Accelerator (COVAX). The company should also publicly commit to not enforcing the exclusive rights of Covid-19 related patents, and enter into non-exclusive, transparent licensing agreements for its Covid-19 products with other companies.
Vaxine has not committed to C-TAP or the MPP.
There is no evidence of the company not enforcing patents.
Vaxine has not signed an agreement with the ACT Accelerator so far.
The vaccine Spikogen was developed jointly with CinnaGen, an Iran-based biotechnology producer. The agreement between the two companies is a cooperation agreement where CinnaGen sponsored phase II and III clinical trials in Iran and will participate in the production process. It seems that SpikoGen (the Iranian replica of Vaxine’s product) is a biosimilar of Covax-19 (Vaxine’s vaccine).
The company should engage in efforts to further equitable distribution of Covid-19 vaccines/therapeutics, by equitably distributing its supplies globally, devising fair pricing strategies, and making the active ingredient for its product available to other manufacturers. The company should also engage in full technology transfer to other manufacturers, including the necessary transfer of skills, legal components, knowledge and intellectual property. Where applicable, the company should agree to waive rights in regulatory test data, and refrain from enforcing TRIPS+ measures.
[Only applies to therapeutics]
CinnaGen is producing a biosimilar of Vaxine’s Spikogen, which involved technology transfer. Vaxine also has a commercial collaboration agreement with Medytox, a biotech company in South Korea: “The partners will jointly carry out product and process development, clinical trial programme and commercial scale-up for the Australian and Asian markets, including Korea.”
